Replies to post #597027 on NorthWest Biotherapeutics Inc (NWBO)

[W_W]

Let me try to explain,

Also, you still have not explained to me why in 2023 CRL is good enough according to LP at the ASM but was not right after data lock?

Going 100% with the CRL right after data lock would create a significant risk, as the CRL could pose a last-minute obstacle or setback. We have seen examples like $IBRX and other companies facing such challenges. However, in 2023, with our own MIA certification in hand, we have more control over our destiny through our MAA. This allows us to approach the CRL with significantly reduced risk for the company. It's similar to how TSLA operates, having its own battery manufacturing facility while also outsourcing to third parties. This approach minimizes risks, provides leverage in contract negotiations with third parties, and ensures capacity requirements are met.

And I dont know why ImmunityBio messed up their manufacturing with their third-party CDMO but there is no other nonrevenue biotech company in the world ever that finances the private CDMO for their CEO instate of outsourcing the drug production to a partner such as CRL.

$IBRX is a clear illustration of the significant risks involved with relying solely on CRL. it's important to note that every new endeavor has a first one. Just like no company, including BP, has had any success in brain cancer so far, so, if you believe NWBo will fail their MAA based on these circumstances, I wish you good luck!"